August 4, 2016 6:47am

… Don’t chase an upside, enjoy it as it happens

Issue, volume is extremely low as appreciation shoots forward, hold on to the reins

 

… Investors should be in a wait-and-see mode ahead of financial results/earnings releases

 

I answer one question; in which company should investors put, keep and commit their money!

 

Where is today’s market going?  Subscribe and find out! 

 

 

Where do investors turn for insight and perspective - I say truthfully what others won't, so you can do what others can't!

 

Companies in my headlights: AGTC, CLLS, PSTI and XON

Indexes and ETFs: The IBB (+0.03%), XBI (+0.03%) are UP while the IWM (-0.17%) and the XLV (-0.08%) are DOWN

Dow futures are UP +0.05 % and NASDAQ futures are DOWN -0.12%

 

U.S. stock index futures indicated a lower open on Thursday morning as traders focused on a host of earnings while keeping a weather eye on a possible rate cut from the Bank of England.

European stocks edged higher as investors digest earnings reports and await the Bank of England's (BoE) rate decision where it is expected to cut interest rates to a record low.

Asia markets advanced, with Japanese shares closing higher after wavering in the morning session as stocks came under pressure from a slightly stronger yen.

 

Data docket: will see initial claims released at 8:30 a.m. ET, with factory orders set to come out at 10:00 a.m. At 7:00 a.m. ET, the Bank of England is widely expected to cut interest rates for the first time since 2009 in an attempt to soften the impact of the U.K's Brexit vote.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed POSITIVE on Wednesday, NEGATIVE on Tuesday, POSITIVE on Monday and NEGATIVE on Friday and last Thursday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

  • Wednesday closed POSITIVE with 7 decliners, 33 advancers and 3 flats;
  • Tuesday closed NEGATIVE with 26 decliners, 15 advancers and 2 flats;
  • Monday closed POSITIVE with 19 decliners, 21 advancers and 3 flats;
  • Friday closed NEGATIVE with 20 decliners, 18 advancers and 5 flats;
  • Thursday closed NEGATIVE with 22 decliners, 15 advancers and 6 flats;

 

 

Remembering Wednesday’s post, “August can be a tough month for stocks with a market that seems lethargic. Enjoy the peaks as they’re timed to expire but, incremental increases are being built-in.   My issue is that we’re getting closer to a large volume of financial results/earnings identifying spending and runways … the same old story!”

  • Why your “hope for a therapy” portfolio may NOT be hopeful?

Never forget, development is essentially an experiment – that’s also why we have phased clinical trials

  • The key takeaway is for investors to recognize that as a “hope” motivated investor; there will be times when it is especially tough to grow assets.

And whereas more investors have recognized periods which lag any market indicator by more than a lot, even defensive portfolios break down more often, as some sector “participants” benefit from their reputation as an investment even as the ride the roller coaster.

 

An investor’s objective is appreciation, I believe that - time to approval will cost you more dollars than investors can even dream or realize well beyond a low volume/high-volatility rotation that is ... IF companies get to "make" it.

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Wednesday up +1.10% and is UP +0.03% in Thursday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Wednesday up +2.13% and is UP +0.03% in Thursday’s  pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed down Wednesday -0.28% and is DOWN -0.08% in Thursday’s pre-market;
  • The iShares Russell 2000 (IWM) closed up +0.80% on Wednesday and is DOWN -0.17% in Thursday’s pre-market.

 

 

Companies in my headlights - the pick and choose list:

Where would I be picking my trading candidate – from last night’s advancers:

•   Adverum (ADVM) +22.32%;

•   Cesca Therapeutics (KOOL) +21.80%;

•   Intrexon (XON) +8.323%;

•   Northwest Bio (NWBO) +6.64%;

•   VistaGen (VTGN) +7.85%

 

From whom would I be picking sort-term investing candidates from last night’s decliners:

•   International Stem Cell (ISCO) -3.54%;

•   Brainstorm (BCLI) -1.61%;

•   Capricor (CAPR) -1.07% after Tuesday’s+3.07%;

•   UniQure (QURE) -0.50% after Tuesday’s +8.55%;

•   Neuralstem (CUR) -0.05%

 

And last night’s flats…

•   Athersys (ATHX) at $2.12;

•   BioLife Solutions (BLFS) at $1.81;

•   ReNeuron (RENE.L) at $3.00;

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.